News

Center for Biosimilars10h
Follow-On Biologics Poised to Expand Global Health Care Access and Lower Costs
Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...
AMGN Q1 Earnings Call: Product Pipeline and Margin Expansion Drive Outperformance
Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.4% ...
New Biologics Reshape the gMG Landscape, but Growth Opportunities Persist for Established and Pipeline Therapies, According to Spherix Global
High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The ...
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
Discover why Dr. Reddy’s Laboratories remains a strong buy amid robust revenue growth, underappreciated pipeline potential, ...
Life Science Business Underpins Our Narrow Moat Rating
We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...